Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

AbbVie’s Humira Loses Only 4% of Market Share to Biosimilars: Report
BioSpace
Tue, 04/9/24 - 11:15 am
Tags:
AbbVie, Humira, biosimilars
For biopharma M&A, the best returns come from small deals: analysts
Fierce Pharma
Tue, 04/9/24 - 11:14 am
Tags:
M&A, Bristol Myers Squibb, AbbVie
Why AbbVie is making big bets on telling the story of its R&D investments
Medical Marketing and Media
Mon, 04/8/24 - 11:56 am
Tags:
AbbVie, R&D
Boehringer to lay off salespeople as Humira biosimilar sales lag
Reuters
Fri, 04/5/24 - 11:33 am
Tags:
Boehringer Ingelheim, AbbVie, Humira, biosimilars, layoffs
Genmab expands US headquarters, plots 300 hires amid launch of AbbVie-partnered lymphoma med Epkinly
Fierce Pharma
Thu, 03/28/24 - 04:59 pm
Tags:
Genmab, Epkinly, AbbVie, hirings, New Jersey
AbbVie to bolster immunity illness drug pipeline with Landos buy
Yahoo/Reuters
Mon, 03/25/24 - 11:38 am
Tags:
AbbVie, Landos Biopharma, immune disorders, M&A
FDA grants full approval to AbbVie's ovarian cancer therapy
Reuters
Sun, 03/24/24 - 10:25 pm
Tags:
AbbVie, ovarian cancer, Elahere
In his final full year as AbbVie's CEO, Richard Gonzalez collects $25.7M in total pay
Fierce Pharma
Tue, 03/19/24 - 11:55 am
Tags:
AbbVie, Pharma CEOs, Richard Gonzalez, executive compensation
AbbVie ends stay with the ADAM family, dropping MacroGenics-partnered ADC in light of early data
Fierce Biotech
Fri, 03/8/24 - 11:07 am
Tags:
AbbVie, IMGC936, ADAM9, solid tumors, Macrogenics
Hugel Aesthetics Breaks Into US Market with Letybo: A New Challenger for Botox
BNN
Mon, 03/4/24 - 11:50 pm
Tags:
Hugel, Letybo, Botox, AbbVie, FDA
ADC Market Will Remain Hot in Oncology, Reaching $30B by 2028: Report
BioSpace
Fri, 03/1/24 - 11:52 am
Tags:
oncology, cancer, antibody-drug conjugate, Merck, AbbVie, Pfizer, AstraZeneca
AbbVie Puts Potential $713M on the Line for OSE’s Inflammation Antibody
BioSpace
Wed, 02/28/24 - 11:12 am
Tags:
AbbVie, OSE Immunotherapeutics, OSE-230, inflammation, monoclonal antibodies
After long road to approval, Teva and Alvotech believe their Humira biosimilar Simlandi may have an edge
Fierce Pharma
Sun, 02/25/24 - 08:57 pm
Tags:
Teva Pharmaceutical, Alvotech, AbbVie, Humira, biosmilars
AbbVie wraps up $64M oncology, immunology deal with Tentarix
Fierce Biotech
Thu, 02/22/24 - 11:28 am
Tags:
AbbVie, Tentarix, onoclogy, immunology
AbbVie’s Cerevel deal hits an uncommon roadblock
BioPharma Dive
Wed, 02/21/24 - 11:10 am
Tags:
AbbVie, Cerevel Therapeutics, M&A, FTC, antitrust
AbbVie CEO Richard Gonzalez to step down, Robert Michael to succeed him
Medical Marketing and Media
Tue, 02/20/24 - 11:39 am
Tags:
AbbVie, Richard Gonzalez, Pharma CEOs, Robert Michael
AbbVie wraps up its $10.1B buyout of ImmunoGen well ahead of schedule
Fierce Pharma
Mon, 02/12/24 - 11:07 pm
Tags:
AbbVie, Immunogen, M&A
Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data
Xtalks
Mon, 02/5/24 - 10:17 am
Tags:
oncology, cancer, Keytruda, Revlimid, Opdivo, Imbruvica, Darzalex, Merck, Bristol Myers Squibb, AbbVie, Janssen
As Humira plummets, AbbVie dials up Rinvoq and Skyrizi estimates to a combined $27B
Fierce Pharma
Fri, 02/2/24 - 11:58 am
Tags:
AbbVie, earnings, Humira, Rinvoq, Skyrizi
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
Reuters
Fri, 02/2/24 - 11:40 am
Tags:
AbbVie, earnings

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.